Most recently, Mr. Glasgow served as a senior vice president for AmerisourceBergen Corporation, where he was part of the business unit focused on specialty drugs. During this engagement, he drove innovation efforts leading to a new "fee of service" model that was responsible for generating more than $150 million in profit for the company.
Prior to AmerisourceBergen, Mr. Glasgow spent more than a decade with FoxMeyer, now part of McKesson, and was previously the chief operating officer of a physician office software and medical claims business.
Earlier in his career, Mr. Glasgow served as a CPA for PricewaterhouseCoopers. He eventually moved into management consulting with the Thomas Group, where he advised a variety of Fortune 500 companies. Mr. Glasgow completed his undergraduate work at Penn State University and earned an MBA from the University of Pittsburgh.
About D2 Consulting
Established in 2008, D2 Consulting (D2) is recognized as the industry's leading provider of commercialization services to the life sciences industry. D2 assists emerging and established pharmaceutical, biopharmaceutical and medical device manufacturers to develop and execute strategic business initiatives, ensuring successful launch, distribution and reimbursement to support an ongoing leadership position in the marketplace.
D2's reach includes the U.S., Canada, Puerto Rico and more than 20 European markets. With more than 300 successful product launches, the Company offers strategic and tactical support services from a core team of advisors with more than 500 years of combined industry experience in more than 50 therapeutic areas. For more information on D2, please visit www.D2rx.com.
Corporate & Media Relations
D2 Consulting, LLC
Lindsay M. Rocco
Elixir Health Public Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/d2-consulting-expands-commercial-solutions-team-with-addition-of-industry-veteran-robert-glasgow-300395813.html
SOURCE D2 Consulting